USPTO serial 86110838
MYCURE
Reviewed by CopyMark Law Group
Status 606
- Filing date
- Status date
- Registration date
- —
- Examiner
- FRAZIER, TAMARA G
- Law office
- INTENT TO USE SECTION
What this means
This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.
Need help with MYCURE?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Bradley P. Hartman
BRADLEY P. HARTMAN HARTMAN TITUS PLC3507 N. CENTRAL AVE.SUITE 101PHOENIX, AZ 85012-2121Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 001 | Chemical test kits for genetic testing for laboratory or research use; Assays and reagents for use in genetic research; Genetic identity tests comprised of reagents; Diagnostic preparations for scientific or research use; Nucleic acid isolation and purification kit consisting primarily of reagents for medical and scientific research purposes; Reagents for scientific or medical research use | ACTIVE | — |
| 005 | Testing kits comprised of medical diagnostic reagents and assays that test for the presence of certain genetic properties; Diagnostic agents, preparations and substances for medical purposes; Medical diagnostic reagents for the analysis of genetic material; Preparations for detecting mutation in prion genes for medical purposes; Clinical diagnostic preparations for medical use; Chemical reagents for medical analysis; Chemical preparation for use in medical analysis, particularly DNA analysis; Pharmaceutical preparations for diagnosis and for identifying and characterizing genetic abnormalities, tracking the progress of disease and measuring the effectiveness of immunotherapy, and for identifying and characterizing immune dysfunction | ACTIVE | — |
| 041 | Consulting services in the field of medical education, namely, providing information about education and training relating to the identification, diagnosis and treatment of medical and genetic conditions; Education services, namely, providing live and on-line continuing professional education seminars in the medical, scientific and genetics field; Education services, namely, providing training programs in the field of genetics; Conducting workshops and seminars in genetic testing and disease identification and treatment; Organization of seminars, working groups, research groups and conventions in the fields of medicine, genetics and scientific research; On-line journals, namely, blogs featuring commentary and information in the fields of DNA identification techniques, practices, and tools; Organization of conferences and symposia for the discussion, dissemination and exchange of scientific data and ideas on topics of interest to the scientific community; Providing educational demonstrations regarding biology, molecular biology, genetics, DNA sequencing and bioinformatics; Conducting educational research for others on the subjects of biology, molecular biology, genetics, genomics, DNA sequencing, and bioinformatics; Conducting classes, seminars and workshops in biology, molecular biology, genetics, genomics, DNA sequencing, bioinformatics and nature study and distributing course materials in connection therewith; Educational services, namely, conducting educational programs in biology, molecular biology, genetics, genomics, DNA sequencing, bioinformatics and nature study; Educational services, namely, conducting on-line exhibitions and displays and interactive exhibits in biology, molecular biology, genetics, genomics, DNA sequencing, bioinformatics and nature study; Organizing exhibitions for education in biology, genetics, genomics, DNA sequencing, bioinformatics and nature study; Providing courses of instruction in the fields of biology, molecular biology, genetics, genomics, DNA sequencing, bioinformatics and nature study and distributing course material in connection therewith; Teaching in the fields of biology, molecular biology, genetics, genomics, DNA sequencing and bioinformatics and nature study | ACTIVE | — |
| 042 | Medical and scientific research in the field of genetic testing and diagnosis and treatment of medical conditions; Development and laboratory testing in the field of genetics and human disease; Medical and scientific research consulting in the field of genetics, genomics, DNA sequencing, and bioinformatics; Consulting services in the field of pharmaceutical research and development and laboratory testing; Genetic research, development and testing services; Genomic research, development and testing services for medical and scientific research purposes; DNA collection, testing and analysis services for medical and scientific research purposes; Genetic testing for diagnostic purposes; Genomic testing for diagnostic purposes; Medical and scientific research, development and consulting in the field of oncology; Medical and scientific research in the field of genetics and genetic engineering; Medical and scientific research and consulting in the fields of genomics and generation sequencing; Medical and scientific research in the field of cancer treatment and diagnosis; Data collection for research purposes, namely, the collection, testing and research of patient molecular and/or genomic data; Scientific clinical studies, namely, conducting clinical trials for others; Retrieval and correlation of genomic data; Medical and scientific research relating to the design and development of cancer treatment therapies; Conducting clinical and pre-clinical trials; Diagnostic services in the field of molecular science, comparative genome analysis, DNA arrays and screening of nucleic acids; Research and development of identification and treatment methods for hereditary factors leading to disease; Identification of target molecules for cancer treatment; Proteogenomic profiling; DNA-sequencing for medical and scientific research purposes; Targeted pharmaceutical drug development services; Genotyping; Gene screening; Gene isolation and gene expression analysis for medical and scientific research purposes; Gene mapping; Gene analysis and biomarker discovery for medical and scientific research purposes | ACTIVE | — |
| 044 | Medical testing for diagnostic or treatment purposes in the field of cancer research; Medical diagnostic testing, monitoring and reporting services; Medical evaluation services; Medical monitoring services; Medical diagnostic, prognostic and theranostic screening and testing; Collection and preservation of DNA for medical and scientific research purposes; Consulting services in the field of healthcare and cancer diagnoses; Providing a website featuring health and healthcare information related to cancer research, testing and screening; Genetic testing for medical purposes; Providing information in the field of cancer prevention, screening, diagnosis and treatment for medical diagnostic and treatment purposes; Providing genetics assessments in the nature of genetic counseling | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by MyCure, LLC
- Other trademarks owned by MyCure, LLC
- Other trademarks in Class 001
- Other trademarks in Class 005
- Other trademarks in Class 041
- Other trademarks in Class 042
- Other trademarks in Class 044
- Similar marks named MYCURE
- Prosecution event MAB6 explained
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Oct 26, 2020 | MAB6 | ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED | The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window. |
| Oct 26, 2020 | ABN6 | ABANDONMENT - NO USE STATEMENT FILED | The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window. |
| Feb 19, 2020 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Feb 18, 2020 | EX5G | SOU EXTENSION 5 GRANTED | — |
| Feb 18, 2020 | AITU | CASE ASSIGNED TO INTENT TO USE PARALEGAL | — |
| Feb 13, 2020 | EXT5 | SOU EXTENSION 5 FILED | — |
| Feb 13, 2020 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Sep 14, 2019 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Sep 12, 2019 | EX4G | SOU EXTENSION 4 GRANTED | — |
| Sep 12, 2019 | EXT4 | SOU EXTENSION 4 FILED | — |
| Sep 12, 2019 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Feb 15, 2019 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Feb 13, 2019 | EX3G | SOU EXTENSION 3 GRANTED | — |
| Feb 13, 2019 | EXT3 | SOU EXTENSION 3 FILED | — |
| Feb 13, 2019 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Sep 12, 2018 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Sep 10, 2018 | EX2G | SOU EXTENSION 2 GRANTED | — |
| Sep 10, 2018 | EXT2 | SOU EXTENSION 2 FILED | — |
| Sep 10, 2018 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Aug 15, 2018 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Mar 15, 2018 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Mar 13, 2018 | EX1G | SOU EXTENSION 1 GRANTED | — |
| Mar 13, 2018 | EXT1 | SOU EXTENSION 1 FILED | — |
| Mar 13, 2018 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Sep 19, 2017 | NOAM | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | A Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date. |
| Jul 25, 2017 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Jul 25, 2017 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Jul 5, 2017 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Jun 20, 2017 | PREV | LAW OFFICE PUBLICATION REVIEW COMPLETED | — |
| Jun 15, 2017 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Jun 1, 2017 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Jun 1, 2017 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Jun 1, 2017 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Jun 1, 2017 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| May 5, 2017 | RCCK | SUSPENSION CHECKED - TO ATTORNEY FOR ACTION | — |
| May 4, 2017 | ALIE | ASSIGNED TO LIE | — |
| Oct 25, 2016 | RCSC | REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED | — |
| Apr 14, 2016 | RCSC | REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED | — |
| Oct 8, 2015 | RCSC | REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED | — |
| Oct 8, 2015 | ALIE | ASSIGNED TO LIE | — |
| Mar 30, 2015 | RCSC | REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED | — |
| Sep 9, 2014 | GNS3 | NOTIFICATION OF LETTER OF SUSPENSION E-MAILED | — |
| Sep 9, 2014 | GNSL | LETTER OF SUSPENSION E-MAILED | — |
| Sep 9, 2014 | CNSL | SUSPENSION LETTER WRITTEN | — |
| Aug 22, 2014 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Aug 21, 2014 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Aug 21, 2014 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Feb 27, 2014 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Feb 27, 2014 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Feb 27, 2014 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Feb 21, 2014 | DOCK | ASSIGNED TO EXAMINER | — |
| Nov 16, 2013 | MPMK | NOTICE OF PSEUDO MARK E-MAILED | — |
| Nov 15, 2013 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |